Percent of subjects with improvement in the Boolean* and SDAI† remission components, radiographic non-progression and remission at week 52 by patient group and treatment
| ETN+MTX | MTX | |||||
|---|---|---|---|---|---|---|
| VERA | ERA | p Value‡ | VERA | ERA | p Value‡ | |
| ≤1 Swollen joint | 74.6 | 70.1¶ | 0.50 | 59.2 | 45.9¶ | 0.11 |
| ≤1 Tender joint | 77.8§ | 65.0¶ | 0.07 | 44.9§ | 46.6¶ | 0.83 |
| CRP ≤1 mg/dl | 87.1§ | 85.0¶ | 0.70 | 69.6§ | 67.6¶ | 0.80 |
| PtGA ≤1 | 28.6 | 31.8 | 0.64 | 14.3 | 23.6 | 0.17 |
| PhGA ≤1 | 69.8§ | 55.4¶ | 0.05 | 40.8§ | 38.5¶ | 0.78 |
| ΔmTSS ≤0.5 | 80.6 | 79.5¶ | 0.85 | 73.9 | 50.0¶ | 0.01 |
| By treatment | ETN+MTX | MTX alone | p Value | |||
| ≤1 Swollen joint | 71.4 | 49.2 | <0.01 | |||
| DAS28 remission** | 54.1 | 32.5 | <0.01 | |||
| SDAI remission†† | 25.3 | 12.2 | <0.01 | |||
| Boolean remission‡‡ | 24.9 | 11.1 | <0.01 | |||
↵* Boolean components include ≤1 swollen joint, ≤1 tender joint, CRP ≤1mg/dl and PtGA ≤1.
↵† SDAI components include swollen joint count, tender joint count, PtGA, PhGA and CRP (data not available for calculating SDAI for all subjects).
↵‡ p Value for disease duration effect.
↵§ p<0.05 For treatment effect within VERA subjects.
↵¶ p<0.05 For treatment effect within ERA subjects.
↵** DAS28 remission defined as score of <2.6.
↵†† SDAI remission defined as score of ≤3.3 (data not available for calculating SDAI for all subjects).
↵‡‡ Boolean remission defined as subjects who simultaneously achieve ≤1 swollen joint, ≤1 tender joint, CRP ≤1 mg/dl and PtGA ≤1.
CRP, C reactive protein; DAS, disease activity score; ERA, early rheumatoid arthritis (4 months to 2 years); ETN, etanercept; mTSS, modified total Sharp score; MTX, methotrexate; PhGA, physician global assessment; PtGA, patient global assessment; SDAI, simplified disease activity index; VERA, very early rheumatoid arthritis (≤4 months).